Pharmaceutical Executive
Its use, new data shows, could boost the economic benefit profile of more “common” drugs-and better inform HTA and payer decision-making.
Barbara Arone
Advertisement
Articles by Barbara Arone
Advertisement
Latest Updated Articles
The Argument for External Comparator AdoptionJune 28th 2019
Advertisement
Advertisement
Trending on PharmExec
1
M&A Roundup: IntraGel & UroGen Sign Collaboration & Investment Agreements, Lupin & Tenpoint Form Commercialization Collaboration
2
Roundup: Amplitude Therapeutics, Chai Discovery Enter Collaborations with Eli Lilly, Bristol Myers Squibb
3
Pharmaceutical Executive Daily: Amplitude Therapeutics Partners with Eli Lilly
4
When Drug Pricing Becomes Trade Policy
5